Document Type
Article
Publication Date
12-1-2022
Abstract
To our knowledge, no prior multicenter clinical trial has reported interobserver agreement of 18F-FDG PET/CT scans for staging of clinical N0 neck in head and neck cancer. Methods: A total of 287 participants were recruited. For visual analysis, positive nodal uptake of 18F-FDG was defined as uptake visually greater than activity seen in the blood pool. Results: The negative predictive value of the 18F-FDG PET/CT for N0 clinical neck was 86% or above for visual assessment (95% CI, 86%-88%) for the 2 central readers and above 90% (95% CI, 90%-95%) for SUVmax for central reads and site reads dichotomized at the optimal cutoff value of 1.8 and the prespecified cutoff value of 3.5, respectively. The κ coefficients between the 2 expert readers and between central reads and site reads varied between 0.53 and 0.78. Conclusion: The NPV of the 18F-FDG PET/CT for N0 clinical neck was 86% or above for visual assessment and above 90% for SUVmax cut points of 1.8 and 3.5 with moderate to substantial agreements.
Recommended Citation
Subramaniam, Rathan M; Duan, Fenghai M; Romanoff, Justin; Yu, Jian Qin; Bartel, Twyla; Dehdashti, Farrokh; Intenzo, Charles M; Solnes, Lilja; Sicks, JoRean; Stack, Brendan C; and Lowe, Val J, "18F-FDG PET/CT Staging of Head and Neck Cancer: Interobserver Agreement and Accuracy—Results from Multicenter ACRIN 6685 Clinical Trial" (2022). Department of Radiology Faculty Papers. Paper 137.
https://jdc.jefferson.edu/radiologyfp/137
PubMed ID
35552246
Language
English
Comments
This article is the author's final published version in Journal of Nuclear Medicine : official publication, Society of Nuclear Medicine, Volume 63, Issue 12, December 2022, Pages 1887 - 1890.
The published version is available at https://doi.org/10.2967/jnumed.122.263902.
Copyright © 2022 by the Society of Nuclear Medicine and Molecular Imaging.